| Cat. No. : |
IL-1beta-82P |
| Description : |
Interleukin-1b is produced by activated macrophages, IL-1B stimulates thymocyte proliferation by inducing il-2 release, b-cell maturation and proliferation, and fibroblast growth factor activity. IL1B proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells. |
| Source : |
Escherichia Coli. |
| Amino Acid Sequence : |
The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Asn-Val-Gln. |
| Physical Appearance : |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Purity : |
Greater than 95.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE. |
| Formulation : |
The protein was lyophilized with no additives. |
| Solubility : |
It is recommended to reconstitute the lyophilized Interleukin-1 alpha in sterile 18 MΩ-cm H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. |
| Protein Content : |
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm using the absorbency value of 0.69 as the extinction coefficient for a 0.1% (1 mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of IL-1b as a Reference Standard. |
| Stability : |
Lyophilized Interleukin 1b although stable at room temperature for 3 weeks, should be stored desiccated below -18℃. Upon reconstitution IL1b should be stored at 4℃ between 2-7 days and for future use below -18℃. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. |
| Pathways : |
Alzheimer"s disease; Apoptosis; Chagas disease; Cytokine-cytokine receptor interaction; Cytosolic DNA-sensing pathway; Graft-versus-host disease; Hematopoietic cell lineage; Leishmaniasis; MAPK signaling pathway; Malaria; NOD-like receptor signaling pathway; Prion diseases; Toll-like receptor signaling pathway; Type I diabetes mellitus |
